ETABLISSEMENT FRANCAIS DU SANG

Their core work

EFS is France's national blood service, responsible for the collection, preparation, and distribution of blood products across the country. Beyond its core transfusion mission, EFS operates advanced research laboratories specializing in cell therapy, regenerative medicine, and blood component science. In H2020 projects, EFS contributes clinical-grade cell manufacturing (particularly mesenchymal stem cells from bone marrow and adipose tissue), plasma processing expertise, and regulatory know-how for advanced therapy medicinal products (ATMPs). Their dual role as both a healthcare operator and a research institution gives them unique access to biological materials, GMP-certified production facilities, and clinical trial infrastructure.

What they specialise in

How they've shifted over time

In 2014–2018, EFS focused broadly on cell therapy applications including stroke treatment (RESSTORE), emergency plasma interventions (Ebola_Tx), and early-stage stem cell trials (ADIPOA2). From 2018 onward, their work narrowed toward orthopedic bone regeneration using MSCs combined with biomaterials and 3D-printed scaffolds (MAXIBONE, ORTHOUNION, MEFISTO), while maintaining their plasma expertise through COVID-19 response (SUPPORT-E). The shift shows a clear move from exploratory cell therapy across multiple indications toward specialized musculoskeletal regenerative medicine with stronger translational and clinical trial design.

EFS is consolidating around MSC-based orthopedic regeneration with 3D biomaterials, making them an increasingly specialized partner for musculoskeletal clinical trials in Europe.

How they like to work

EFS participates exclusively as a partner, never as coordinator, which reflects their role as a specialized contributor bringing clinical-grade cell production and biological materials to consortia led by universities or hospitals. With 110 unique partners across 15 countries in just 9 projects, they work in large, multinational consortia — typical of multi-center clinical trials. Their consistent participation across related projects suggests they are a trusted, repeat contributor in the European regenerative medicine community rather than a one-off partner.

EFS has collaborated with 110 distinct partners across 15 countries, reflecting their involvement in large multi-center clinical trial consortia spanning most of Western and Southern Europe. Their network is broad and pan-European rather than concentrated in any single geographic cluster.

What sets them apart

EFS combines the scale and regulatory standing of a national public health institution with active research capabilities in cell therapy and regenerative medicine — a rare combination in Europe. Unlike university labs, EFS can manufacture clinical-grade cell products under GMP conditions at industrial scale, making them an essential partner for any consortium moving stem cell therapies from bench to bedside. Their direct access to blood and tissue donations, plus established regulatory pathways for advanced therapy medicinal products, removes bottlenecks that slow down other research groups.

Highlights from their portfolio

• MAXIBONE
  Largest single EC contribution to EFS (EUR 1.6M), combining personalized 3D-printed biomaterials with autologous MSCs for maxillofacial bone regeneration — their most ambitious translational project.
• SUPPORT-E
  Rapid COVID-19 response project evaluating convalescent plasma across Europe, demonstrating EFS's ability to mobilize its plasma expertise for public health emergencies.
• RESSTORE
  Large-scale stroke recovery trial using allogenic stem cells, representing EFS's most clinically ambitious work outside their orthopedic focus.